Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR.
|
29030743 |
2017 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using this approach, we identified the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor.
|
24520024 |
2014 |
Follicular thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using real-time PCR, western blot and IHC analysis, ST6GalNAcII differed in three follicular thyroid cancer cell lines (FTC133, primary and FTC238, lung metastasis).
|
26820593 |
2016 |
Thyroid cancer, follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using real-time PCR, western blot and IHC analysis, ST6GalNAcII differed in three follicular thyroid cancer cell lines (FTC133, primary and FTC238, lung metastasis).
|
26820593 |
2016 |
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The present study investigated the alteration in expression of ST6GalNAcII involved in invasion and to clarify the possible mechanism of ST6GalNAcII in the metastasis process in human follicular thyroid carcinoma cell lines.
|
26820593 |
2016 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study is to clarify the possible role and mechanism of ST6GalNAcII in the metastasis process of breast carcinoma.
|
24756995 |
2014 |
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The SIATL1 gene, encoding STM, was mapped to the long arm of human chromosome 17 at q23-qter, a region that is nonrandomly deleted in human breast cancers.
|
11984005 |
2002 |
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Suppression of these miRNAs implicated an inverse function, while altered expression of ST6GALNAC2 mediated CRC progression upon transfection with miR-135b/-182 mimic or inhibitor.
|
28767179 |
2017 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.
|
24596201 |
2014 |
IGA Glomerulonephritis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that potential genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity, and may contribute to the polygenic nature of IgAN.
|
19357720 |
2009 |
Major Depressive Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of ST6GALNAC2 was decreased in leukocytes from patients with MDD.
|
28844310 |
2018 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, we observed an enrichment of mutations in genes (B3GNT2, B4GALT2, ST6GALNAC2) involved in the biosynthesis of N- and Cores 1-3 O-linked glycans in the colon, accounting for ~16% of the CRCs tested.
|
27004849 |
2016 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In Gal-1-deficient mice, MCAM-silenced (MCAM(KD)) or ST6GalNAc2-overexpressing (ST6(O/E)) melanoma cells exhibited slower growth rates, underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth.
|
25756799 |
2015 |
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, taken together, our results imply that ST6GalNAcII activated the invasion in follicular thyroid cancer cells through regulating the activity of PI3K/Akt pathway.
|
26820593 |
2016 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, Southern analyses indicated that SIATL1 is usually not grossly rearranged in breast tumors.
|
11984005 |
2002 |
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, miR-182/-135b inhibited significantly ST6GALNAC2 expression, and consistently, ST6GALNAC2 mediated migration, adhesion, invasion, proliferation, and tumor angiogenesis in CRC cell lines.
|
29030743 |
2017 |
IGA Glomerulonephritis
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Expression of ST6GALNAC2 in B peripheral lymphocytes was significantly lower in patients with IgAN than that in normal controls (3.7 +/- 2.2 versus 6.3 +/- 2.3, P = 0.016); alpha2,6-ST activity in B lymphocytes was correlated positively with the level of alpha2,6-sialic acid in serum IgA1 in patients (n = 42) and controls (n = 12) (r = 0.37, P = 0.007).
|
19170967 |
2009 |